The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Colorectal cancer updates at ASCO 2022
Mark Yarchoan, MD, Johns Hopkins Medicine, Baltimore, MD, reflects on key updates presented at this year’s American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the use of neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer, as well as the continuing investigation of circulating tumor DNA (ctDNA). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
